Why the study?
Most atherosclerosis studies and recent technologies are conducted in cell cultures and animal models, leaving a need for better understanding in human tissues.
CD34 progenitor cells and CD68 macrophages are highly expressed in early and advanced atheroma, whereas smooth muscle cells predominate in the fibroatheroma stage of human coronary atherosclerosis.
Marker shifts in experimental atheroma should not alter practice; leaves open validation of CD68/CD34 targeting in human plaque progression.
BACKGROUND: Atherosclerosis is a widespread and devastating disease and one of the leading causes of death worldwide. So much is there to understand about atherosclerosis. And although a lot is already discovered, yet most of the studies are performed in cell cultures and animal models. Recent technologies for genetic engineering and imaging are mainly performed on animal models, with few studies in human tissues. A better understanding of their role is required. AIM: We aim to study the expression of CD 34 hematopoietic progenitor stem cell, CD 68 macrophages, and smooth muscle actin (SMA)-positive smooth muscle cells (SMCs) in the human coronary arteries and correlate their differential expression with the atherosclerosis progression. RESULTS: CD 68 and CD 34 expression increase as the atherosclerotic process proceeds from early atheroma to advanced atheroma and start to decrease as the process proceeds to fibroatheroma with a significant p < 0.001. Conversely, SMA expression decreases as the atherosclerotic process progresses with a significant p < 0.001. CONCLUSION: CD34 progenitor cells in conjunction with CD 68 macrophages have a major role in the development of atherosclerosis, whereas the SMCs are minimal in the early stages and reach their maximal levels during the stage of fibroatheroma.
No takes yet. Share an insight, caveat, or question.
Kamel et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: